Good day,
We are excited to introduce you to a new way to receive The Early Bird's "Stock of the Day" a day before the stock idea shows up in The Early Bird's email newsletter.
Our free "Stock of the Day" service is delivered via SMS so that you can see each stock pick right away.
Each morning, you'll receive:
- Actionable stock picks, hand selected by MarketBeat's team of expert research analysts.
- Headlines and market insights for each selected ticker.
- A bull case and a bear case to help inform your next move.
- Timely updates and alerts so that you can capitalize quickly on each opportunity.
Ready to take your investing and trading to the next level?
Click Here to Receive The Early Bird's Stock of the Day (Free)
Best regards,
The Early Bird Team
JNJ Stock Surge Signals Confidence in New Growth Path
Written by Jeffrey Neal Johnson. Published 8/25/2025.
Key Points
- The company's separation from its consumer health business has created a leaner enterprise focused on high-margin innovation and performance.
- A robust oncology and immunology pipeline is delivering substantial growth and creating a clear path for future revenue, strengthening investor confidence.
- Strategic acquisitions are supercharging the MedTech division's growth, while its long history as a Dividend King underscores its financial stability.
Johnson & Johnson's (NYSE: JNJ) stock chart is sending a clear signal that stands in sharp contrast to the steady stream of negative headlines. While news cycles remain fixated on long-running legal battles, the company's shares have climbed more than 23% year-to-date—a vote of confidence from the market.
This widening gap between headlines and performance points to a fundamental shift at the healthcare giant. At its core, the strategic spinoff of the consumer health business has forged a leaner, more focused Johnson & Johnson.
Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)
In 2004, one man called Nvidia before just about anyone knew it existed.
Now, this same guy says a new company could become the next to soar like Nvidia.
Today, the company is dedicated to the high-margin, high-growth frontiers of innovative medicine and medical technology. For investors, the narrative is moving beyond legacy lawsuit risks to a clear path toward future growth.
A Leaner Core, A Stronger Bottom Line
In 2023, J&J separated its slower-growth, lower-margin consumer division into Kenvue (NYSE: KVUE), unlocking shareholder value and transforming the parent into a pure-play pharmaceuticals and MedTech company.
That streamlined structure is now bearing fruit, allowing the firm's growth engines to run at full throttle. In the second quarter of 2025, total revenue reached $23.74 billion from its two primary segments: Innovative Medicine ($15.20 billion) and MedTech ($8.54 billion).
Management responded by raising full-year sales guidance by $2 billion at the midpoint, underscoring the strength of its refocused strategy. By concentrating capital on high-return R&D and selective acquisitions, J&J is well positioned for margin expansion and sustained growth.
How New Medicines Are Defying Headwinds
J&J's pharmaceutical division continues to outperform, driven by a deep pipeline of high-impact therapies that offset patent cliffs and other headwinds.
- Oncology Leadership: The Oncology franchise grew operational sales by 22.3% in Q2, led by multiple myeloma blockbuster Darzalex (+21.5%) and Carvykti, the next-generation cell therapy whose sales more than doubled to $439 million.
- Stelara Transition: Although Stelara faces loss of exclusivity, the roll-out of its successor, Tremfya, is proceeding smoothly. Tremfya sales rose 30.1% as it gains traction in new IBD indications.
- Pipeline Catalysts: A robust late-stage pipeline de-risks long-term growth. The FDA granted Priority Review to TAR-200, an innovative delivery system with multibillion-dollar peak sales potential in bladder cancer. Meanwhile, J&J has filed for approval of icotrokinra, a first-in-class oral therapy for psoriasis.
How Shrewd Deals Are Supercharging Growth
J&J's MedTech division is an equally vital growth pillar, fueled by targeted, high-impact acquisitions. In Q2, the segment recorded 6.1% operational growth, with its cardiovascular business surging 22%.
Key deals—Abiomed's heart pump technology and Shockwave Medical's breakthrough treatment for calcified arteries—are already exceeding expectations and cementing J&J's leadership in high-growth cardiovascular markets. This M&A strategy adds diversification, strengthens cash flow, and provides the resilience to manage long-term liabilities like talc litigation without derailing innovation.
The Complete Package: Growth Meets Stability
For decades, Johnson & Johnson has been a cornerstone holding for long-term investors. Its transformation into a focused pharmaceuticals and MedTech powerhouse only reinforces this status. Trading at a forward P/E of 16.88, the stock balances growth potential with financial discipline.
- Elite Dividend King: J&J has increased its dividend for 64 consecutive years, underscoring its durability through all market cycles.
- Reliable Yield and Payout: A 2.91% dividend yield and a payout ratio of 55.6% of earnings support both income and future growth potential.
No investment is without risk, but Johnson & Johnson's deliberate reinvention has created a clearer, more potent growth trajectory. Between a robust drug pipeline, strategic MedTech expansion, and an unshakeable dividend track record, the company presents a compelling case for long-term value.
MarketBeat empowers individual investors to make better investment decisions by offering real-time financial information and objective investment analysis.
This email message is a paid sponsorship for The Early Bird, a third-party advertiser of MarketBeat. Why did I receive this email content?.
If you need assistance with your newsletter, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. U.S.A..